Gabriel Hinojosa, PharmD, BCOP, explores unmet needs and social determinants in multiple myeloma care, envisioning treatment advancements amid evolving complexities and patient disparities.
Faculty offer insights on the NEXICART-1 phase 1 clinical trial investigating the safety and efficacy of NXC-201 in patients with AL amyloidosis and discuss potential clinical implications on the study’s findings.